C188-9 reduces TGF-β1-induced fibroblast activation and alleviates ISO-induced cardiac fibrosis in mice.
Jiao LiuYuxuan JinBei WangJinying ZhangShengkai ZuoPublished in: FEBS open bio (2021)
Cardiac fibrosis is the final event of heart failure and is associated with almost all forms of cardiovascular disease. Cardiac fibroblasts (CFs), a major cell type in the heart, are responsible for regulating normal myocardial function and maintaining extracellular matrix homeostasis in adverse myocardial remodeling. In this study, we found that C188-9, a small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), exhibited an antifibrotic function, both in vitro and in vivo. C188-9 decreased transforming growth factor-β1-induced CF activation and fibrotic gene expression. Moreover, C188-9 treatment alleviated heart injury and cardiac fibrosis in an isoproterenol-induced mouse model by suppressing STAT3 phosphorylation and activation. These findings may help us better understand the role of C188-9 in cardiac fibrosis and facilitate the development of new treatments for cardiac fibrosis and other cardiovascular diseases.
Keyphrases
- left ventricular
- cardiovascular disease
- heart failure
- transforming growth factor
- gene expression
- high glucose
- extracellular matrix
- small molecule
- diabetic rats
- mouse model
- epithelial mesenchymal transition
- type diabetes
- emergency department
- cystic fibrosis
- dna methylation
- endothelial cells
- drug induced
- adipose tissue
- inflammatory response
- skeletal muscle
- signaling pathway
- toll like receptor
- protein protein